New Covid-19 cases in Bahrain cross 1,000 after two months

TDT | Manama      

The Daily Tribune – www.newsofbahrain.com

Staff Reporter

New cases of Covid-19 in Bahrain crossed the 1,000 mark for the first time yesterday after a space of nearly two months. The Health Ministry reported 1,008 cases yesterday, highlighting the need to exercise caution in the coming days.

Speaking to The Daily Tribune, a leading medical practitioner warned that the battle against the pandemic is not yet over and the existing success must persist in the coming days as well.

The rising numbers of Covid-19 cases comes amid the Kingdom remaining on alert against the threat caused by Monkeypox cases, which are increasing across the world.

The Kingdom’s existing success against the pandemic is attributed to its vaccination milestones and preventive measures adopted by the Ministry of Health.

As of now, the Kingdom has approved Pfizer/BioNTech Comirnaty, Gamaleya Sputnik Light, Gamaleya Sputnik V, Johnson and Johnson Ad26.COV2.S, Covishield AstraZeneca, Bharat Biotech Covaxin, Sinopharm Covilo and ValnevaVLA2001.

Bahrain became the first country in the world to authorise, receive and administer Valneva’s Covid-19 vaccine manufactured by the French biotech major. A recent study published by the Nature Magazine showed that the risk of Covid infection, intensive care unit admissions and deaths remained high among recipients of the Sinopharm vaccine in the Kingdom.

The study, carried out by Dr Sid Mukherjee, a researcher in the field, probes into the Kingdom’s Covid-19 related outcomes from a national database, taking into consideration the administering of four vaccines to tackle the pandemic risk.

“Despite the overall effectiveness of all four vaccines in decreasing the risk of COVID-19 related hospitalisations, intensive care unit admissions and deaths, we noted a significantly higher risk of SARS-CoV-2 infection, hospitalisations and ICU admissions among recipients of the Sinopharm vaccine compared to other vaccine recipients.”